Abstract
The increasing resistance of bacteria and fungi to currently available antibiotics is a major concern worldwide, leading to enormous efforts to develop new antibiotics with new modes of actions. Antibacterial peptide CM4 (ABP-CM4) is a small cationic peptide with broad-spectrum activities against bacteria, fungi, and tumor cells, which may possibly be used as a promising candidate for a new antibiotic. For pharmaceutical applications, a large quantity of antimicrobial peptides needs to be produced economically. In this communication, the progress in the structural characteristics, heterologous production, and biological evaluation of ABP-CM4 are reviewed.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Amino Acid Sequence
-
Anti-Infective Agents / metabolism
-
Anti-Infective Agents / pharmacology
-
Antimicrobial Cationic Peptides / biosynthesis*
-
Antimicrobial Cationic Peptides / genetics
-
Antimicrobial Cationic Peptides / pharmacology
-
Circular Dichroism
-
Cloning, Molecular
-
Escherichia coli / drug effects
-
Escherichia coli / genetics
-
Escherichia coli / metabolism
-
Fungi / drug effects
-
Gene Expression
-
Humans
-
Microbial Sensitivity Tests
-
Models, Molecular
-
Molecular Sequence Data
-
Pichia / genetics
-
Pichia / metabolism
-
Protein Structure, Secondary
-
Recombinant Fusion Proteins / biosynthesis*
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / pharmacology
Substances
-
Anti-Infective Agents
-
Antimicrobial Cationic Peptides
-
CM4 peptide, Bombyx mori
-
Recombinant Fusion Proteins